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Acute and chronic graft versus host disease (GVHD) are
major limiting factors for the success of allogeneic hemato-
poietic cell transplantation (alloHCT) as curative therapy for
haematological malignancies. Though the occurrence of
GVHD is controlled in part by non-speciﬁc T cell directed
immunosuppression, this contributes to disease relapse and
increased risk of infections. Dendritic cells (DC) direct
immune responses and reinforce regulatory mechanisms.
Targeting DC activation as a novel immunosuppressive
strategy may limit the generation of deleterious T cell
responses and preserve regulatory T cell responses, whilst
preserving T cell responses to leukemia and pathogens. We
have shown that presence of activated CMRF-44+CD11c+ DC
predicts for acute GVHD after clinical alloHCT (Trans-
plantation 2007;83:839). This may reﬂect systemic activation
of blood DC or their migration after activation. Our recent
data associating CCR5 expression on CD16+ DC with clinical
acute GVHD (submitted) supports the latter concept. Such
observations may enable earlier intervention with current
agents or potentially new mAb targeting activated DC. Mice
with human PBMC xenograft undergoing early graft versus
host disease events have CMRF-44+CD11c+ DC. We have
shown efﬁcacy of an anti-human CD83 antibody in pre-
venting xenogenic GVHD but preserving protective anti viral
and leukemic responses (J Exp Med 2009;206:387). Similar
efﬁcacy of anti CD83 antibody in mouse alloHCT was re-
ported recently (BMT 2011;46 Suppl:P837). Our ongoing
studies focus on human DC subpopulations in clinical
alloHCT. We have now identiﬁed activated CMRF-44+ DC in
chronic GVHD and shown that they decline with effective
extracorporeal photochemotherapy. This justiﬁes the
extended evaluation of new human anti CD83 mAb and new
CMRF-44 like mAb being developed in our laboratory as
potential new immunosuppressive agents. Current studies
conﬁrm their ability to inhibit human immune responses in
vitro and in vivo and we plan to test these new anti-DC
therapeutics in Phase 1 studies in alloHCT.
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Identiﬁcation and Typing of Killer-Cell Immunoglobulin-
Like Receptors (KIRs) Using Quantitative PCR Assay
Reagents for Research
Persis P. Wadia 1, Doug Bost 2. 1 Product Development, Quest
Diagnostics, Alameda, CA; 2 Celera, Alameda, CA
Aim: Recent publications demonstrate after an allogeneic
hematopoietic cell transplant (HCT), anti-leukemia effects
are primarily provided by Tcells and Natural Killer (NK) cells.
NK cells play a role in reduced graft versus host disease and
in increased graft versus leukemia effects predominantly due
to their cell surface receptors namely Killer-cell immuno-
globulin-like receptors (KIRs). Conventional KIR genotypingmethods involve sequence-speciﬁc primer (SSP)-PCR or
sequence speciﬁc oligonucleotide hybridization PCR fol-
lowed by visualization of PCR products by agarose gel elec-
trophoresis or using sequence-based typing. Lack of
a universal test to type KIR combined with the low
throughput and high costs of existing methodologies
prompted the development of a prototype quantitative PCR
(qPCR) assay for KIR genotyping. The prototype assay uses
ﬂuorescent hydrolysis probes and may provide accurate and
fast KIR genotyping with minimal DNA to aid in KIR geno-
typing for pre and post-transplantation research.
Methods: Panel of 24 DNA containing common KIR geno-
types was obtained from UCLA DNA exchange. 240 ng total
DNA for 16 KIR reactions (each reaction run in triplicate) was
used for the prototype qPCR assay and results were
compared with a PCR-SSP KIR genotyping kit utilizing 3 ug
total DNA. The prototype assay consists of reagents to
perform multiplexed KIR genotyping which is ampliﬁcation
of a KIR gene and an internal qPCR reference gene for
normalizations, quantiﬁcation, and conﬁrmation of true
absence of KIR genes.
Results: The prototype qPCR assay results were 100%
concordant with the commercial PCR-SSP kit. The qPCR assay
accurately detected each KIR gene with a 12 fold reduction in
the amount of DNA required. There was no-post PCR analysis
or additional specialized equipment with all KIR genes being
ampliﬁed under the same thermocycling conditions.
Conclusions: We have shown feasibility for a prototype
qPCR assay for KIR genotyping that is robust and ﬂexible for
both small and large scale genetic analysis studies. With
implications of KIR in transplantation (particularly in AML
HCT), autoimmune and infectious diseases, and pregnancy-
related complications, faster detection might aid earlier
therapy intervention and a more sensitive assay can poten-
tially identify previously unidentiﬁed novel associations.
Genotyping KIRs using qPCR based assays could be useful in
both clinical and basic research settings.406
Haploidentical Allogeneic Hematopoietic Stem Cell
Transplantation for the Treatment of Refractory/Relapsed
Acute Leukemia
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Feng-rong Wang, Jing-zhi Wang, Hai-xia Fu, Xiao-jun Huang.
Institute of Hematology, Peking University People's Hospital,
Beijing, China
Objective: To retrospectively analyze the results of refrac-
tory/relapsed acute leukemia patients who received human
leukocyte antigen (HLA)-mismatched/haploidentical alloge-
neic hematopoietic stem cell transplantation (allo-HSCT) and
to perform risk factor analysis.
Methods: Of the 96 refractory/relapsed acute leukemia(AL)
patients, 56 patients suffered from acute myeloid leuke-
mia(AML) and 35 patients suffered from acute lymphoid
leukemia (ALL), all in non-remission(NR) or relapse before
transplant. Most patients received conditioning therapy
comprised of modiﬁed busulfan/cyclophosphamide (BuCy)
plus thymoglobulin (ATG).
Results: With a median follow-up of 373d(34-3157d), 33/
96(34%) survived, 31/96(32%) survived without leukemia,
35/96(36%) relapsed. The estimated 3-year overall survival
(OS) and disease-free survival (DFS) of the 96 cases was 30.2%
and 29.0%. The 3-year OS were signiﬁcantly higher for AML
patients (39.2%) than for ALL patients (15.4%) (P ¼ .005), the
OS probability of patients with prophylactic donor
